Description
This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immunity and/or reduction of morbidity and mo…
Amendment chain · 4 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $6,659,050 at start, $5,176,172 after amendment #3 (−$1,482,878).
- #02022-09-01$6,659,050
- #12023-02-28$4,926,172-$1,732,878
- #22023-06-12$5,426,172+$500,000
- #32024-03-25$5,176,172-$250,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2022-09-01(start date) | $6,659,050 | — | This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effect… |
| #1 amendment | 2023-02-28 | $4,926,172 | −$1,732,878 | This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effect… |
| #2 amendment | 2023-06-12 | $5,426,172 | +$500,000 | This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effect… |
| #3 amendment | 2024-03-25 | $5,176,172 | −$250,000 | This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effect… |
Related records · 11
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 842333817)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2024-2025-Q1-1018795 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $11,642 | FY2025 |
| 172-2020-2021-Q4-966282 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $37,933 | FY2021 |
| 172-2020-2021-Q3-961167 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $2,780,109 | FY2021 |
| 172-2020-2021-Q2-955668 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $38,170 | FY2021 |
| 172-2020-2021-Q3-960196 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $85,232 | FY2021 |
| 172-2020-2021-Q1-951033 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $71,148 | FY2021 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2022-2023-Q2-995430 · retrieved 2026-11-12.